Stock comparison
IDEXX Laboratories
Incyte
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
INCY
Incyte
Market cap
$20.04B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | INCY | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 63C | IDXX |
| Benjamin Graham | 80A | 73B | IDXX |
| Philip Fisher | 75B | 61C | IDXX |
| Peter Lynch | 71B | 50C | IDXX |
| Joel Greenblatt | 83C | 45D | IDXX |
| Charlie Munger | 87A | 60C | IDXX |
| Terry Smith | 84A | 66B | IDXX |
Side-by-side metrics
| Metric | IDXX | INCY |
|---|---|---|
| Market cap | $42.11B | $20.04B |
| P/E (TTM) | 39.0x | 14.0x |
| EV/EBIT | 31.6x | 12.4x |
| ROIC (TTM) | 40.66% | 19.98% |
| Gross margin | 62.05% | 91.86% |
| Net margin | 24.63% | 26.71% |
| Revenue CAGR 5y | 7.56% | 14.55% |
| EPS CAGR 5y | 10.79% | 11.26% |
| Debt / Equity | 0.7x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$42.11Bvs $20.04B+52%
- ROIC (TTM)40.66%vs 19.98%+51%
INCY leads on
- Debt / Equity0.0xvs 0.7x+99%
- P/E (TTM)14.0xvs 39.0x+64%
- EV/EBIT12.4xvs 31.6x+61%
- Revenue CAGR 5y14.55%vs 7.56%+48%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.